Currently, a clinical trial is underway to assess the safety, tolerability, pharmacokinetics, and efficacy of HS‐10352 in combination with fulvestrant in patients with PIK3CA‐mutant, HR‐positive, HER2‐negative advanced breast cancer (NCT05504213). Here, PIK3CA is linked to breast cancer.